Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Study Identifier
192024-030
CT.gov Identifier
NCT00652496
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.01% ophthalmic solution
  • Bimatoprost 0.015% formulation 1 ophthalmic solution
  • Bimatoprost 0.015% formulation 2 ophthalmic solution
  • Bimatoprost 0.02% ophthalmic solution
  • Bimatoprost 0.03% ophthalmic solution
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Ocular hypertension or glaucoma in both eyes * Require IOP-lowering therapy in each eye
    Exclusion Criteria:
    * Uncontrolled systemic disease * Known allergy or hypersensitivity to bimatoprost

    Protocol Summary

    This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

    Study Locations

    Location
    Status
    Location
    Wenatchee, Washington, United States
    Status
    Not applicable